Increased levels of circulating ICAM-1, E-selectin, and IL-2 receptors in celiac disease
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
10711458
DOI
10.1023/a:1005489316037
Knihovny.cz E-zdroje
- MeSH
- celiakie krev dietoterapie MeSH
- dítě MeSH
- dospělí MeSH
- E-selektin krev MeSH
- kojenec MeSH
- lidé MeSH
- mezibuněčná adhezivní molekula-1 krev MeSH
- mladiství MeSH
- předškolní dítě MeSH
- receptory interleukinu-2 krev MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- E-selektin MeSH
- mezibuněčná adhezivní molekula-1 MeSH
- receptory interleukinu-2 MeSH
Adhesive interactions between endothelium and circulating cells are crucial for the development of inflammatory reactions. We found significantly higher serum levels of soluble intracellular adhesion molecule-1 (sICAM-1, 492.5 +/- 22.1 ng/ml) in patients with active celiac disease (including IgA-deficient patients) than in patients on a gluten-free diet (335.7 +/- 20.0 ng/ml) (P < 0.001) and healthy controls (207.4 +/- 11.2 ng/ml) (P < 0.001). The concentration of soluble E-selectin in sera from celiac patients (37.2 +/- 3.4 ng/ml) was also higher (P < 0.001) than in sera from healthy controls (15.5 +/- 0.7 ng/ml) but, in contrast to sICAM-1, it remained high in the patients after treatment (30.2 +/- 2.7 ng/ml). Interestingly, the concentration of circulating soluble interleukin-2 receptors, molecules indicating lymphocyte activation, was only increased in sera from patients with active celiac disease (2943.0 +/- 214.1 pg/ml), and the level in sera from treated patients and healthy controls was comparable (1936 +/- 349 and 1416 +/- 111.7 pg/ml). The elevated serum level of soluble cell adhesion molecules could be used as a supplementary, noninvasive procedure for monitoring intestinal immune reactions.
Zobrazit více v PubMed
Ann N Y Acad Sci. 1992 Dec 4;667:324-31 PubMed
J Gastroenterol. 1997 Aug;32(4):480-6 PubMed
Annu Rev Immunol. 1993;11:767-804 PubMed
Nephrol Dial Transplant. 1994;9(7):770-4 PubMed
Ital J Gastroenterol. 1993 Apr;25(3):109-16 PubMed
Arch Dis Child. 1990 Aug;65(8):909-11 PubMed
J Rheumatol. 1995 Mar;22(3):406-12 PubMed
Dig Dis Sci. 1996 Sep;41(9):1780-5 PubMed
Res Commun Mol Pathol Pharmacol. 1995 Jan;87(1):21-6 PubMed
Ann Clin Lab Sci. 1995 Jan-Feb;25(1):44-51 PubMed
Gut. 1990 May;31(5):497-9 PubMed
Gastroenterology. 1998 Dec;115(6):1317-21 PubMed
Immunol Today. 1989 Dec;10(12):417-22 PubMed
Gastroenterology. 1998 Jul;115(1):211-6 PubMed
Clin Immunol Immunopathol. 1996 Jun;79(3):203-10 PubMed
Am J Gastroenterol. 1995 Aug;90(8):1301-6 PubMed
Annu Rev Immunol. 1987;5:223-52 PubMed
Nature. 1988 Feb 18;331(6157):624-7 PubMed
Transplantation. 1993 Jan;55(1):83-7 PubMed
Dig Dis Sci. 1997 Nov;42(11):2277-84 PubMed
Clin Immunol Immunopathol. 1992 May;63(2):196-9 PubMed
Clin Exp Immunol. 1990 Dec;82(3):489-92 PubMed
Clin Immunol Immunopathol. 1997 Dec;85(3):289-96 PubMed
Gut. 1999 Feb;44(2):168-73 PubMed
Eur J Gastroenterol Hepatol. 1995 May;7(5):455-60 PubMed
J Immunol. 1986 Sep 15;137(6):1893-6 PubMed
Gliadin peptides activate blood monocytes from patients with celiac disease
